OJRM  Vol.2 No.2 , June 2013
Clinical translation of neuro-regenerative medicine in India: A study on barriers and enabling strategies
ABSTRACT

We present the findings of a study of barriers and enabling strategies to clinical translation of Neuro-Regenerative Medicine (Neuro-RM) technologies in India. Twenty-three people were included in this qualitative study, including researchers, clinicians, firm representatives and policy makers working in Neuro-RM. The study has identified barriers that may arise at each stage of translation and how these are being addressed. Understanding of the molecular and cellular basis of Neuro-RM is being supported through government investment in existing neuroscience centres and the creation of new centres with regenerative medicine expertise. Clinical trials benefit from the support of clinicians who partner with researchers in study design and data collection. Government agencies have developed guidelines to inform best practices in preclinical and clinical studies. Addressing the barriers to Neuro-RM translation identified in this study can be achieved through continued support for capacity building and priority setting in preclinical studies, international efforts to achieve clinical trial protocol standardization, and multidisciplinary collaborations between clinicians, researchers, government and industry.


Cite this paper
Messih, M. , Emerson, C. , Thorsteinsdóttir, H. , Fehlings, M. and Daar, A. (2013) Clinical translation of neuro-regenerative medicine in India: A study on barriers and enabling strategies. Open Journal of Regenerative Medicine, 2, 20-27. doi: 10.4236/ojrm.2013.22004.
References
[1]   Kim, J., Schafer, J. and Ming, G.L. (2006) New directions in neuroregeneration. Expert Opinion on Biological Therapy, 6, 735-738. doi:10.1517/14712598.6.8.735

[2]   Shaji, K.S., Jotheeswaran, A.T., Girish, N., et al. (2009) The dementia India report: Prevalence, impact, costs and services for dementia. Report Prepared for the Alzheimer’s & Related Disorders Society of India.

[3]   Daar, A.S. and Greenwood, H.L. (2007) A proposed definition of regenerative medicine. Journal of Tissue Engineering and Regenerative Medicine, 1, 179-184. doi:10.1002/term.20

[4]   Littman, B.H., Di Mario, L., Plebani, M. and Marincola, F.M. (2007) What’s next in translational medicine? Clinical Science, 112, 217-227.

[5]   Gourie-Devi, M. and Organization of Neurology Services in India (2008) Unmet needs and the way forward. Neurology India, 56, 4-12. doi:10.4103/0028-3886.39304

[6]   World Health Organization (2006) Neurological disorders: Public health challenges. World Health Organization, Geneva.

[7]   Greenwood, H.L., Singer, P.A., Downey, G.P., Martin, D.K., Thorsteinsdóttir, H. and Daar, A.S. (2006) Regenerative medicine and the developing world. PLOS Medicine, 3, 1496-1500. doi:10.1371/journal.pmed.0030381

[8]   Owens, D.F. and Panchision, D.M. (2012) Institutional profile: National Institute of Neurological Disorders and Stroke and National Institute of Mental Health. Regenerative Medicine, 7, 33-36. doi:10.2217/rme.11.106

[9]   Munoz-Sanjuan, I. and Bates, G.P. (2011) The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. Journal of Clinical Investigation, 121, 476. doi:10.1172/JCI45364

[10]   Tandon, P.N. (2009) Transplantation and stem cell research in neurosciences: Where does India stand? Neurology India, 57, 706-714. doi:10.4103/0028-3886.59464

[11]   International Society for Stem Cell Research (2009) ISSCR guidelines for the clinical translation of stem cells. Current Protocols in Stem Cell Biology, Appendix 1B.

[12]   Department of Biotechnology. Centers of Excellence and Programme Support in Areas of Biotechnology. http://dbtindia.nic.in/uniquepage.asp?id_pk=20

[13]   Government of India. Stem Cell Biotechnology. http://dbtindia.nic.in/uniquepage.asp?ID_PK=20

[14]   Totey, S.M. and Kayshyap, S.D. (2005) Tissue system with undifferentiated stem cells derived from corneal limbus. WIPO A01N 1/00.

[15]   All Indian Institute of Medical Sciences. Stem Cell Facility Project. http://www.aiims.edu/aiims/stemcell/project.htm

[16]   BS Reporter (2010) Cipla ties up with stempeutics for stem cell therapies. Business Standard.

[17]   Reliance Life Sciences. http://www.rellife.com/products_relinethra.html

[18]   Department of Biotechnology. Centers of Excellence and Programme Support in Areas of Biotechnology. http://dbtindia.nic.in/uniquepage.asp?id_pk=20

[19]   Lenka, A. and Anand, A. (2009) Advancements in stem cell research—An Indian perspective. Annals of Neuroscience, 16.

[20]   Indian Council of Medical Research. Stem Cell Guidelines. http://www.icmr.nic.in/stem_cell/stem_cell_guidelines.pdf

[21]   Bartunek, J., Dimmeler, S., Drexler, H., et al. (2006) The consensus of the task force of the European Society of Cardiology concerning the clinical investigation of the use of autologous adult stem cells for repair of the heart. European Heart Journal, 27, 1338-1340. doi:10.1093/eurheartj/ehi793

[22]   Freedman, M.S., Bar-Or, A., Atkins, H., et al. (2010) The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: Consensus report of the International MSCT Study Group. Multiple Sclerosis Journal, 16, 503-510. doi:10.1177/1352458509359727

[23]   Stern, J.M. and Simes, R.J. (1997). Publication bias: Evidence of delayed publication in a cohort study of clinical research projects. British Medical Journal, 13, 7109.

[24]   Stern, J.M. and Simes, R.J. (1997) Publication bias: Evidence of delayed publication in a cohort study of clinical research projects. British Medical Journal, 13, 7109.

[25]   Sabat, S. and Harre, R. (1992) The construction and deconstruction of self in Alzheimer’s disease. Ageing & Society, 12, 443-461. doi:10.1017/S0144686X00005262

[26]   Small, J.A., Geldart, K., Gutman, G. and Clarke-Scott, M.A. (1998) The discourse of self in dementia. Ageing & Society, 18, 291-316.

[27]   Gibson, G., Timlin, A., Curran, S. and Wattis, J. (2004) The scope for qualitative methods in research and clinical trials in dementia. Age and Ageing, 33, 422-426. doi:10.1093/ageing/afh136

[28]   Steeves, J.D., Lammertse, D., Curt, A., Fawcett, J.W., et al. (2006) Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: Clinical trial outcome measures. Spinal Cord, 45, 206-222. doi:10.1038/sj.sc.3102008

[29]   Norquist, B.M., Goldberg, B.A. and Matsen III, F.A. (2000) Challenges in evaluating patients lost to follow-up in clinical studies of rotator cuff tears. The Journal of Bone & Joint Surgery, 82, 838.

[30]   Katz, J.S. and Martin, B.R. (1997) What is research collaboration? Research Policy, 26, 1-18. doi:10.1016/S0048-7333(96)00917-1

[31]   Bozeman, B. and Corley, E. (2004) Scientists’ collaboration strategies: Implications for scientific and technical human capital. Research Policy, 33, 599-616. doi:10.1016/j.respol.2004.01.008

[32]   Thorsteinsdóttir, H., Melon, C.C., Ray, M., Chakkalackal, S., Li, M., Cooper, J.E., et al. (2010) South-south entrepreneurial collaboration in health biotech. Nature Biotechnology, 28, 407-416. doi:10.1038/nbt0510-407

[33]   Bertrand, F., Picard-Aitken, M., Lecomte, N., et al. Summative evaluation of the networks of centres of excellence—New initiatives final evaluation report. http://www.sshrc-crsh.gc.ca/about-au_sujet/publications/NCE-NI_FinalE.pdf

 
 
Top